Palvella Therapeutics (PVLA) Retained Earnings (2013 - 2026)
Palvella Therapeutics (PVLA) posted quarterly Retained Earnings of -$151.2 million for Q1 2026, down 5039900.0% year-over-year from N/an in Q1 2025, and down 11.63% quarter-over-quarter from -$135.4 million in Q4 2025.
Palvella Therapeutics (PVLA) Retained Earnings (2013 - 2026) Analysis & Trends
Palvella Therapeutics (PVLA) has reported Retained Earnings for 14 consecutive years, with -$151.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings fell 5039900.0% year-over-year to -$151.2 million; the TTM figure through Mar 2026 stood at -$151.2 million (down 5039900.0% YoY), while the FY2025 annual figure was -$135.4 million, down 4515100.0% from the prior year.
- Retained Earnings retreated to -$151.2 million in Q1 2026 per PVLA's latest filing, from -$135.4 million in the prior quarter.
- Across five years, Retained Earnings topped out at $342.9 million in Q3 2024 and bottomed at -$323.4 million in Q2 2024.
- Historically, Retained Earnings has averaged -$94.0 million across 5 years, with a median of -$123.4 million in 2025.
- Annual changes were most pronounced in 2022 — Retained Earnings jumped 391.24% — and 2026, when it tumbled 5039900.0%.
- Palvella Therapeutics' Retained Earnings stood at -$254000.0 in 2022, then sank by 122104.72% to -$310.4 million in 2023, then soared by 100.0% to $3000.0 in 2024, then plunged by 4515100.0% to -$135.4 million in 2025, then fell by 11.63% to -$151.2 million in 2026.
- Business Quant data shows PVLA's Retained Earnings at -$151.2 million in Q1 2026, -$135.4 million in Q4 2025, and $104000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Palvella Therapeutics | 2.25 Bn | 1.93 Bn | - | 389.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 389.85 Mn |
| Mar 31, 2026 | -151.20 Mn |
| Dec 31, 2025 | -135.45 Mn |
| Sep 30, 2025 | 104,000.00 |
| Jun 30, 2025 | -111.40 Mn |
| Mar 31, 2025 | -3,000.00 |
| Dec 31, 2024 | 3,000.00 |
| Sep 30, 2024 | 342.92 Mn |
| Jun 30, 2024 | -323.40 Mn |
| Mar 31, 2024 | 342.17 Mn |
| Sep 30, 2023 | -310.40 Mn |
| Jun 30, 2023 | -299.63 Mn |
| Mar 31, 2023 | -303.60 Mn |
| Dec 31, 2022 | -254,000.00 |
| Sep 30, 2022 | -282.32 Mn |
| Jun 30, 2022 | -272.58 Mn |
| Mar 31, 2022 | 953,000.00 |
| Dec 31, 2021 | -257.14 Mn |
| Sep 30, 2021 | -247.61 Mn |
| Jun 30, 2021 | -231.08 Mn |